Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Pending · due 31 Dec 2026

Rules 1.1.0 · as of 14 Sep 2026

Quote

“Top-lines from Sanmai, Brainsonix, and other tFUS companies are likely to make news too.”
· Ten 2026 Predictions on Which to Hang Your Hat. · substack post

Item 4 of the 2026 predictions list, continued: top-line results from transcranial focused ultrasound companies Sanmai, Brainsonix and others will make news in 2026.

Intake

EventA proposition written from a template on the asset, with a resolution criterion and a named public source, before the outcome is looked up. The same event resolves every person's items on it. Method ›
Sanmai transcranial focused ultrasound trial reports topline results
AreaOne of five topic classes: regulatory decisions, clinical trial outcomes, company and market outcomes, payer and policy, practice adoption. Every event has one area. Method ›
Trial outcomes
DeadlineThe date by which the event must happen for the item to be true. It comes only from the person's words through the anchor table. Method ›
31 Dec 2026 AnchorThe fixed table that turns the person's own words ('by 2026', 'Q2', 'within two years') into a deadline. The coder never invents a date. Method › · “2026 predictions list ('Ten 2026 Predictions on Which to Hang Your Hat.', published 1 January 2026)”
Probability
0.70 LexiconThe fixed five-bin table that turns a phrase into a probability. The strongest phrase in the claim sentence decides; coders never read tone. Method › · binOne of five lexicon steps: A 'will' 0.90, B 'probably' 0.70, C 'may' 0.50, D 'unlikely' 0.30, E 'never' 0.10. A stated number goes to the nearest bin for calibration only. Method › B · “are likely to make news too”
Base rateThe probability a published external study gives an event of that class and stage, fixed at intake. Halved when the item window is shorter than the class median time to decision. Never learned from the ledger's own items. Method ›
None in the table
Tags
retrospective
Coder BCohen's kappa: agreement between two coders beyond chance, from -1 to 1. Reported for admit, event, deadline, bin and asserts from the second-coder match test. Method ›
admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · event E-0052 · deadline 31 Dec 2026 · bin B
Registry entry

Sanmai, or the investigators of a clinical trial of Sanmai's transcranial focused ultrasound therapy, publicly report topline (primary-outcome) results of that trial, in any direction.

TRUE on the date of the first sponsor topline press release, ClinicalTrials.gov results posting or peer-reviewed publication, dated after 2026-01-01, that reports primary-outcome results (positive, negative or mixed) of a clinical trial of a Sanmai transcranial focused ultrasound treatment in human participants. Trial-start or enrollment announcements, preclinical or healthy-volunteer mechanistic data without a clinical primary outcome, conference teasers without primary-outcome results, and results already public on the statement date do not count. FALSE at the deadline when no such report is dated by then. Resolution source: Sanmai press releases, with ClinicalTrials.gov results and PubMed as secondary sources.

Resolution source: Sanmai press releases (company newsroom); ClinicalTrials.gov results and PubMed as secondary sources

Readings: 'Top-lines' = topline (primary-outcome) results of a clinical trial; the forecaster asserts no direction, so a positive, negative or mixed result all count.; 'Make news' is read as the public release of the results; press coverage is not required.; 'Sanmai, Brainsonix, and other tFUS companies' is 'A and B': Brainsonix is coded at owen-2026-b; 'other tFUS companies' is an uncountable set and is not coded.

How to read
The event, criterion and deadline were written at intake, before the outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method › was looked up. Coder B coded the statement independently.

Coder A

Resolution

State
PendingAn item whose deadline has not passed. Counted, never scored. Method ›
Effective deadlineAn item enters the score only when its deadline has passed and the outcome is true or false. A claim already known true still waits for its deadline. Method ›
31 Dec 2026
Outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method ›
not occurred · checked through 13 Sep 2026
Resolver note
Checked the Sanmai newsroom, ClinicalTrials.gov and PubMed on 2026-09-13. ClinicalTrials.gov lists two Sanmai-sponsored studies: NCT06169631 (anxiety, status unknown, no results posted) and NCT07207122 (Parkinson disease tFUS pilot, recruiting, primary completion December 2026, last updated 2026-07-31, no results posted). The Sanmai news page has no item after June 2025 and no topline announcement. PubMed returns no Sanmai-sponsored trial result. The only 2026 tFUS paper found (Biological Psychiatry Global Open Science, 2026-04-10, Virginia Tech, 40 healthy volunteers, Focused Ultrasound Foundation funded) is not a Sanmai trial and is healthy-volunteer mechanistic work, which the criterion excludes. No topline (primary-outcome) report of a Sanmai tFUS trial dated after 2026-01-01 exists as of 2026-09-13.
BrierThe squared gap between a probability and the outcome, (p - o)^2. 0 is perfect, 0.25 is the constant coin flip, 1 is confidently wrong. Lower is better. Method ›
Not scored
How to read
State at window close; the outcome comes from the registry, the score from the rule.

Registry

Timeline

1 claim against 11 events in the field.

saiddueevent
17 Feb 2026 · Compass Pathways (COMP360, COMP006): Second phase 3 COMP006 meets primary endpoint: two 25 mg COMP360 doses 3 weeks a5 Mar 2026 · Helus Pharma (HLP004 / CYB004, GAD): Helus reports phase 2 signal-detection results for deuterated DMT HLP004 in mode1 Apr 2026 · Alto Neuroscience (ALTO-101): Alto's phase 2 proof-of-concept of ALTO-101 in cognitive impairment associated w8 Apr 2026 · AtaiBeckley (BPL-003): AtaiBeckley publishes phase 2a data of BPL-003 in TRD patients on SSRIs (CNS Dru26 May 2026 · US Department of Veterans Affairs: VA launches its MDMA-assisted therapy trial for veterans with PTSD and alcohol u15 Jun 2026 · Neumora Therapeutics (navacaprant, KOASTAL-2/3): KOASTAL-2 and KOASTAL-3 both miss; Neumora discontinues navacaprant after three 22 Jun 2026 · Definium Therapeutics (DT120 / MM120, Emerge): Phase 3 Emerge of single-dose DT120 (LSD) ODT 100 µg in MDD meets its primary en7 Jul 2026 · Compass Pathways (COMP360, COMP006): COMP006 26-week (Part B) data show benefit of two 25 mg doses maintained on aver21 Jul 2026 · Helus Pharma (HLP003 / CYB003, APPROACH): Helus completes enrollment in the phase 3 APPROACH study of HLP003 as adjunctive12 Aug 2026 · Definium Therapeutics (DT120 / MM120, Voyage): Phase 3 Voyage of DT120 ODT 100 µg in GAD meets its primary HAM-A endpoint at we9 Sep 2026 · Compass Pathways (COMP360, COMP005 Part C): Compass reports 52-week open-label COMP005 data: participants who received an adCOMPASS PATHWAYS (COMP360, COMP005 PART C): COMPASS REPORTS 52-WEEK OPEN-LABEL COMP005 DATA: PARTICIPANTS WHO RECEIVED AN ADSANMAI TRANSCRANI…Sanmai transcranial focused ultrasound trial reports topline results · stated 1 Jan 2026Sanmai transcranial focused ultrasound trial reports topline results · restated 1 Jan 2026 · p 70%70%TODAY2026

Trial outcomes